One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction

While bodyweight reduction should be a primary intervention target in obese heart failure with preserved ejection fraction (HFpEF) patients, no pharmacological treatments have shown evidence. The STEP HFpEF trial 1 Kosiborod M.N. Abildstrøm S.Z. Borlaug B.A. Butler J. Rasmussen S. Davies M. Hovingh G.K. Kitzman D.W. Lindegaard M.L. Møller D.V. et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 2023; 389: 1069-1084https://doi.org/10.1056/NEJMoa2306963 Crossref PubMed Scopus (158) Google Scholar showed that semaglutide significantly improved various aspects of heart failure-related clinical outcomes in obese HFpEF patients, along with remarkable weight loss. While bodyweight reduction should be a primary intervention target in obese heart failure with preserved ejection fraction (HFpEF) patients, no pharmacological treatments have shown evidence. The STEP HFpEF trial 1 Kosiborod M.N. Abildstrøm S.Z. Borlaug B.A. Butler J. Rasmussen S. Davies M. Hovingh G.K. Kitzman D.W. Lindegaard M.L. Møller D.V. et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. 2023; 389: 1069-1084https://doi.org/10.1056/NEJMoa2306963 Crossref PubMed Scopus (158) Google Scholar showed that semaglutide significantly improved various aspects of heart failure-related clinical outcomes in obese HFpEF patients, along with remarkable weight loss.